Carboplatin & Paclitaxel (CP)
CP: Carboplatin & Paclitaxel
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Forde et al. 2022 (CheckMate 816) | 2017-2019 | Phase 3 (C) | 1a. CP & Nivolumab 1b. CVb & Nivolumab 1c. DC & Nivolumab |
Inferior EFS |
Note: there were additional comparator options depending on histology; see the respective histology-specific pages for more details. This study was conducted in the United States. The reason for the study was that an unanswered question at the time was whether adding an immune checkpoint inhibitor would improve outcomes.
Biomarker eligibility criteria
- CheckMate 816: No sensitizing EGFR or ALK mutations
Chemotherapy
- Carboplatin (Paraplatin) AUC 5 or 6 IV once on day 1
- Paclitaxel (Taxol) 175 or 200 mg/m2 IV once on day 1
21-day cycle for 3 cycles
Subsequent treatment
References
- CheckMate 816: Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N; CheckMate 816 Investigators. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022 May 26;386(21):1973-1985. Epub 2022 Apr 11. link to original article contains dosing details in manuscript PubMed NCT02998528
Start of hidden/commented information for virtual editor End of hidden/commented information for virtual editor
Start of comment inserted by visual editor(edited again by visual editor)
(edited again by visual editor end)End of comment inserted by visual editor
HemOnc.org - A Free Hematology/Oncology Reference
Links to all main disease pages
back to top |
back to top |
Transplant | |||
Stem cell mobilization | Allogeneic HSCT | Autologous HSCT | Graft versus host disease (GVHD) |
back to top |
Additional Information
Created as a knowledge base for hematology & oncology providers, HemOnc.org is a collaborative wiki containing details about 100's of hematology/oncology drugs, and 1000's of treatment regimens. Content is added by hematology & oncology professionals, and undergoes continuous peer review.
Any information that one feels would be helpful to other oncology providers is welcome. Visit how to contribute for more details.
Priorities of this project include:
- Creating a database of all FDA-approved chemotherapy agents and supportive medications used in the field of hematology/oncology.
- Creating a database of all standard-of-care chemotherapy regimens and references to primary literature (PubMed and direct links to the abstracts/full articles).
- Sample order sets and examples of supportive medications used with treatment regimens
- Aggregating useful links to existing resources by disease, such as information about prognosis, clinical calculators, staging, and patient resources.
Additional possibilities for this project may include:
- Creating summaries of pivotal clinical trials
- Prioritizing regimens by their efficacy and/or toxicity
- Capturing historical regimens that were standard-of-care prior to 2005
- Checklists for common clinical scenarios/diseases
- Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects
The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource. The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access. We believe that the familiar format of a Wiki, made popular by sites such as Wikipedia, will significantly help ease-of-use and navigation.